National Yang Ming Chiao Tung University

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan

Institute of Nuclear Energy Research, Atomic Energy Council

Hsin-Ell Wang

Wuu-Jyh Lin

Hao-Wen Kao

Kun-Liang Lin

Chien-Chung Hsia

Mao-Chi Weng

Shun-Fu Chang

Chao-Cheng Chen

Kwan-Hwa Chi

Jia-Je Li

Der-Chi Tien

Jenn-Tzong Chen

Ting-Shien Duh

Keng-Li Lan

Li-Yuan Huang

Cheng Allen Chang

Pei-Chia Chan

Chuan-Lin Chen

C Allen Chang

Roy Chen-Chih Wu

Wen-Yi Chang

The present invention provides a targeted prodrug enzyme fusion carrier comprising a targeted molecule and a prodrug enzyme. The targeted prodrug enzyme fusion carrier can effectively identify and bind to tumor cells and tumor-induced tumor angiogenesis. The targeted prodrug enzyme fusion carrier also has a targeted prodrug enzyme fusion protein and a theranostic system utilizing the method of in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors.

Targeted prodrug cytosine deaminase fusion carrier and application thereof

A dual targeting drug carrier is provided. The dual targeting drug carrier comprises a first targeting molecule and a second targeting molecule, wherein the targeting molecule comprises peptide, protein or antibody. The targeting molecule can bind to specific receptors, proteins, or glycoproteins to recognize the specific tumor cells, tissues, or organs. The dual targeting drug carriers are further conjugated with imaging agents, radioactive molecules (radiopharmaceuticals, isotopes, or chemotherapeutic drugs) or nanoparticles to form a conjugate.

Dual targeting drug carrier and application thereof

The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.

Radiolabeled active targeting pharmaceutical composition and the use thereof

AF-labeled monomeric galactose derivative is provided as a tomography probe. The derivative is a positron emission tomography (PET) probe. The derivative has high affinity and good stability in animal's body. The derivative can be an alternative glucose metabolism imaging agent used in clinic examination and quantification.

18F-labeled monomeric galactose derivative used as tomography probe

Growing community of inventors

Taoyuan County, Taiwan

Hsin-Ell Wang